Nervi, Clara, Ferrara, Fabiana F., Fanelli, Mirco, Rippo, Maria Rita, Tomassini, Barbara, Ferrucci, Pier Francesco, Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811, Gelmetti, Vania, Gambacorti-Passerini, Carlo, Diverio, Daniela, Grignani, Francesco, Pelicci, Pier Giuseppe and Testi, Roberto 1998. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 92 (7) , pp. 2244-2251. 10.1182/blood.V92.7.2244 |
Abstract
All-trans-retinoic acid (RA) treatment induces morphological remission in acute promyelocytic leukemia (APL) patients carrying the t(15;17) and expressing the PML/RARalpha product by inducing terminal differentiation of the leukemic clone. RA treatment induces downregulation of PML/RARalpha and reorganization of the PML-nuclear bodies. These events have been proposed to be essential for the induction of APL cell differentiation by RA. Here, we show that in the APL-derived NB4 cell line as well as in myeloid precursor U937 cells expressing the PML/RARalpha (U937/PR9) and in blasts from APL patients, the PML/RARalpha fusion protein is cleaved by a caspase 3-like activity induced by RA treatment. In fact, a caspase 3-like activity is detectable in PML/RARalpha expressing cells after RA treatment, and selective caspase inhibitor peptides are able to prevent the RA-induced degradation of the fusion protein in vivo and in vitro. Using recombinant caspases and PML/RARalpha deletion mutants we mapped a caspase 3 cleavage site (Asp 522) within the alpha-helix region of the PML component of the fusion protein. The extent of PML/RARalpha cleavage directly correlates with the ability of RA to restore the normal PML nuclear bodies (NBs) pattern. However, RA-induced differentiation is not prevented by the persistence of the fusion product and occurs in the absence of normally structured PML NBs. These results indicate that PML/RARalpha is directly involved in conferring RA sensitivity of APL cells and that the RA-induced reassembly of PML NBs is the consequence of the disappearance of PML/RARalpha.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Publisher: | American Society of Hematology |
ISSN: | 0006-4971 |
Date of Acceptance: | 10 July 1998 |
Last Modified: | 01 Mar 2024 15:00 |
URI: | https://orca.cardiff.ac.uk/id/eprint/166044 |
Actions (repository staff only)
Edit Item |